Swiss National Bank Has $101.20 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Swiss National Bank decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 514,980 shares of the medical research company’s stock after selling 25,800 shares during the quarter. Swiss National Bank owned 0.28% of IQVIA worth $101,199,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Synergy Asset Management LLC acquired a new position in IQVIA during the fourth quarter worth about $33,000. Avior Wealth Management LLC raised its stake in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares in the last quarter. Assetmark Inc. raised its stake in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares in the last quarter. Meeder Asset Management Inc. raised its stake in IQVIA by 353.7% during the third quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company’s stock worth $58,000 after acquiring an additional 191 shares in the last quarter. Finally, Versant Capital Management Inc increased its stake in shares of IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after buying an additional 93 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

IQVIA stock opened at $185.40 on Friday. The stock has a market capitalization of $32.69 billion, a price-to-earnings ratio of 24.72, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $256.34. The stock’s 50 day moving average price is $196.63 and its two-hundred day moving average price is $210.95. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

IQV has been the subject of several recent research reports. Stephens initiated coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Stifel Nicolaus lowered their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Truist Financial reaffirmed a “buy” rating and issued a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Finally, William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.